This may be explainable by the upregulation of EZH2 in SMARCB1-deficient tumours, which enhances CXCR4 expression through the repression of the tumour-suppressive microRNAs miR-622 and miR-9 [51,52]. This evidence concerns the gene SMARCB1 and neoplasm.